Related Experiment Video
Updated: Jun 27, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Management of myelodysplastic syndromes: 2008 update
1University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA. bscott@fhcrc.org
Abstract:
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells

